TEL-AML-1 fusion gene resulting from 12,21 chromosomal translocation is believed to be the most common molecular genetic abnormality in childhood acute lymphoblastic leukemia(ALL). This study has been conducted to investigate the frequency of this fusion gene in children suffering from ALL attending the oncology unit in Basra hospital for pediatric and gynecology during the period from May 2009...

Numerous factors impact on the prognosis of acute myeloid leukemia (AML), among which molecular genetic abnormalities are developed increasingly, however, accurate prediction for newly diagnosed AML patients remains unsatisfied. For further improving the prognosis evaluation system, we investigated the transcripts levels of PDCD7, FIS1, FAM3A, CA6, APP, KLRF1, ATCAY, GGT5 and Ang2 in 97 AML pat...

Genome and transcriptome profiling methods are increasingly used in studies of pediatric acute myeloid leukemia (AML). AML can be distinguished from acute lymphoblastic leukemia (ALL) on the basis of gene expression profiles; so too can the various subclasses of these two forms be further distinguished and genetically characterized. Genome-wide analysis studies (GWAS) have also contributed to n...

OBJECTIVE To describe the epidemiological profile and the survival rate of patients with acute myeloid leukemia (AML) in a state reference pediatric hospital. METHOD Clinical-epidemiological, observational, retrospective, descriptive study. The study included new cases of patients with AML, diagnosed between 2004 and 2012, younger than 15 years. RESULTS Of the 51 patients studied, 84% were ...

INTRODUCTION Acute myeloblastic leukemia (AML) accounts for 15 to 25 percent of childhood acute leukemias. The most common genetic abnormalities seen in pediatric AML patients are AML1-ETO, PML-RARα and CBFB-MYH11 genes resulting in t(8;21), t(15;17) and inv(16). These genetic defects are seen in approximately 20-25% of AML patients. OBJECTIVE We investigated in this study, incidence and prog...

Acute myeloid leukemia (AML) is a rapidly progressive, poor prognosis malignant tumor caused by hematopoietic stem cells/progenitor cells. In recent years, there have been significant advances in basic and preclinical research on AML. Compared with traditional chemotherapy, cell transplantation (HSCT) significantly improved prognosis. However, high recurrence rates low 5-year survival rates, mo...

Acute myeloid leukemia (AML) is a disease characterized by neoplastic transformation and abnormality of progenitor cells differentiation from cells. In AML there heterogeneous in hematopoietic cells, this has been identified affects the balance between proliferation, survival body Mutation FMS-like tyrosin kinase 3 (FLT3) gene causes overexpression which one most often found mechanism that coul...

Objective: To investigate the efficacy and prognosis of venetoclax combined with hypomethylating agents (HMAs) in treatment relapsed/refractory acute myeloid leukemia (AML). Methods: From June 2021 to February 2022, 14 patients AML were treated HMAs, among which nine + azacytidine, while five decitabine. The treatments was observed, followed up. Results: All received one courses treatment, medi...